Actively Recruiting
Phase 2 Study of Oral Isoquercetin to Lower Blood Clot Risk in People With Ovarian Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-07-29
90
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating whether isoquercetin can reduce blood markers that may indicate the risk of blood clots in people with ovarian cancer. This randomized, double-blind, placebo-controlled Phase 2 trial compares the effects of isoquercetin with a placebo in participants receiving first-line chemotherapy. The study aims to understand how isoquercetin influences thrombin generation related to clot risk in this patient group. Participants are assigned to one of three groups a placebo group, an isoquercetin once-daily group, or an isoquercetin twice-daily group. The study drug is taken orally and is coordinated to start on the first or second cycle of chemotherapy. The trial continues for up to six weeks from baseline to measure changes in thrombin generation. During the study, participants undergo regular blood tests to measure platelet-dependent thrombin generation compared to baseline. Researchers monitor organ and marrow function to ensure safety, and participants must agree to use contraception if of child-bearing potential. The primary measurement focuses on changes in clotting markers within six weeks, with ongoing safety monitoring throughout the trial period, which ends in 2032.
CONDITIONS
Brief Title
A Study of Isoquercetin in People With Ovarian Cancer
Research Team
J
Jeffrey Zwicker, MD
E
Elizabeth Jewell, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
